Investor + Media Resources

Upcoming Conferences
May 29, 2020

Geneos will be attending the following upcoming conferences:

  • SITC, Nov. 2020, FL
  • Neoantigen Summit, Nov. 2020, MA

GT-30: cGMP Manufacturing of First Clinical Lot
May 18, 2020

VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy

View PDF

Hepatocellular Carcinoma Trial
February 3, 2020

Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial


View PDF

Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 30, 2020

Geneos Therapeutics Named One of 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. Niranjan Y. Sardesai, CEO of Geneos, presented at the Lyfebulb Helsinn Cancer Innovation Summit on January 30th, 2020 in Monaco.

Establish Supply Agreement
July 19, 2019

Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics

View PDF

Announcing First Patient Dosed
July 10, 2019

Geneos Therapeutics Announces First Patient Dosed
with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

View PDF

Anticancer Immunity
February 24, 2019

Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines

View PDF

Next Gen Neoantigen-Targeting Immunotherapies
February 21, 2019

Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

View PDF